Latest Breaking News On - Targeted drug therapy - Page 3 : comparemela.com

Daiichi Sankyo: Datopotamab Deruxtecan Plus Durvalumab Showed Promising Clinical Activity in the First-Line Advanced Non-Small Cell Lung Cancer Setting in TROPION-Lung04 Phase 1b Trial

Daiichi Sankyo: Datopotamab Deruxtecan Plus Durvalumab Showed Promising Clinical Activity in the First-Line Advanced Non-Small Cell Lung Cancer Setting in TROPION-Lung04 Phase 1b Trial
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Siteman cancer centerUnited statesWashington universityBaden wübergMark rutsteinJennifer brennanDaiichi sankyoSaiama waqarAnn oncCristian massacesiKoji ogiwaraInternational agency for research on cancerWorld health organizationWashington university school of medicineOncology clinical developmentAmerican cancer society

Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients with Advanced Non Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial

TOKYO & BASKING RIDGE, N.J. (BUSINESS WIRE) Jul 3, 2023

United statesJennifer brennanSusan galbraithKen takeshitaAnn oncKoji ogiwaraDaiichi sankyoDaiichi sankyo co ltdDaiichi sankyo incAnticancer researchInternational agency for research on cancerSapporo medical universityAmerican cancer societySarah cannon research instituteWorld health organizationGlobal head

AstraZeneca s Dato-DXd significantly improved PFS in lung cancer

AstraZeneca's Dato-DXd significantly improved PFS in lung cancer

United statesSusan galbraithAnn oncDaiichi sankyoKen takeshitaAmerican cancer societyAnticancer researchInternational agency for research on cancerWorld health organizationExecutive vice presidentGlobal headInternational agencyLung factAccessed julyNon small cell lung cancerTargeted drug therapy

AstraZeneca (AZN) Reports Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival

AstraZeneca (AZN) Reports Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesKen takeshitaKoji ogiwaraAnn oncDaiichi sankyoSusan galbraithJennifer brennanDaiichi sankyo incInternational agency for research on cancerAmerican cancer societySapporo medical universityDaiichi sankyo co ltdWorld health organizationSarah cannon research instituteAnticancer researchGlobal head

Datopotamab deruxtecan met dual primary endpoint of progression-free survival in patients with advanced non-small cell lung cancer in TROPION-Lung01 Phase III trial

Positive high-level results from the TROPION-Lung01 Phase III trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant improvement for the dual primary endpoint of progression-free survival (PFS) compared to docetaxel, the current standard of care chemotherapy, in patients with .

United kingdomUnited statesSusan galbraithDaiichi sankyoKen takeshitaAnn oncAmerican cancer societyLung ambition allianceAnticancer researchInvestor relations teamSapporo medical universityWorld health organizationCompany on twitter astrazenecaInternational agency for research on cancerFirst phaseExecutive vice president